NCT03849430 Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients
| NCT ID | NCT03849430 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Glioma of Brain |
| Study Type | OBSERVATIONAL |
| Enrollment | 750 participants |
| Start Date | 2015-12-14 |
| Primary Completion | 2030-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 750 participants in total. It began in 2015-12-14 with a primary completion date of 2030-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gliomas are the most common primary intracranial tumors, representing at least 75% of all primary malignant brain tumors. Histopathologically, gliomas are classified into different subgroups including astrocytomas (60-70%), oligodendrogliomas (10-30%), ependymomas (\<10%) and mixed gliomas (i.e. oligoastrocytomas) depending on the cell type from which they originate. The World Health Organization currently classifies gliomas based on histopathological analysis in which the presence (or absence) and the degree of specific histopathological features determines the grade of malignancy. Grade I (pilocytic astrocytoma) and grade II (diffuse astrocytoma, oligodendroglioma, mixed oligoastrocytoma, and pleomorphic xanthoastrocytoma) are termed low-grade gliomas (LGGs), whereas grade III (anaplastic astrocytoma, anaplastic oligodendroglioma or anaplastic oligoastrocytoma) and grade IV (glioblastoma) represent high-grade gliomas (HGGs). Given the incurable nature of gliomas, the maintenance or improvement of the patient's quality of life are extremely important. The benefits of multimodal treatment strategies, in terms of prolonged survival or delay of progression, have to be carefully balanced against the side effects of the treatment, which may adversely influence patient's functioning and well-being during his/her remaining life span. Measuring a brain tumor patients functioning and well-being goes far beyond assessing (progression-free) survival or tumor response to treatment on imaging. A more integrated way to measure patients functioning and well-being is the assessment of a patient's health-related quality of life (HRQOL). HRQOL is defined as a personal self-assessed ability to function in the physical, psychological, emotional, and social domains of day-to-day life. The main goal of this study is to perform a large-scale, prospective and long-term analysis of the HRQOL in patients diagnosed with glioma.
Eligibility Criteria
Inclusion criteria: * age ≥ 18 years * patients diagnosed and treated for a high- or low grade glioma * treatment in UZ Leuven
Contact & Investigator
Steven De Vleeschouwer, MD Phd
PRINCIPAL INVESTIGATOR
UZ Leuven
Frequently Asked Questions
Who can join the NCT03849430 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioma of Brain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03849430 currently recruiting?
Yes, NCT03849430 is actively recruiting participants. Contact the research team at steven.devleeschouwer@uzleuven.be for enrollment information.
Where is the NCT03849430 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT03849430 clinical trial?
NCT03849430 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Steven De Vleeschouwer, MD Phd at UZ Leuven. The trial plans to enroll 750 participants.